


RECEIVED  
FEB 1 2002  
TECH CENTER 1600/2900

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Horst Fischer and Beate Illek  
Application No. : 09/982,315  
Filed : October 17, 2001  
For : COMPOSITIONS AND METHODS FOR CYSTIC FIBROSIS  
THERAPY

Art Unit : 1623  
Docket No. : 200116.403D1  
Date : January 25, 2002

Commissioner for Patents  
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.



Respectfully submitted,

Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Jane E.R. Potter  
Registration No. 33,332

JEP:sfl

Enclosures:

Postcard  
PTO/SB/21  
Form PTO-1449  
Cited References (18)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

D:\NrPortbl\iManage\SHANEL\252102\_1.DOC


FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 200116.403D1		APPLICATION NO. 09/982,315	
<b>INFORMATION DISCLOSURE STATEMENT</b> <small>(Use several sheets if necessary)</small>				APPLICANTS <b>Horst Fisher and Beate Illek</b>		<b>RECEIVED</b> <b>FEB 11 2002</b> <b>TECH CENTER 1600/290</b>	
				FILING DATE October 17, 2001			
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	5,639,661	06/17/97	Welsh and Sheppard	435	252.3	
	AB	5,972,995	10/26/99	Fischer et al.	514	456	
	AC	6,329,422 B1	12/11/01	Fischer et al.	514	456	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION	
						YES NO	
	AD	WO 99/18953	04/22/99	WIPO			
<b>OTHER PRIOR ART</b> <small>(Including Author, Title, Date, Pertinent Pages, Etc.)</small>							
	AE	Abstract of JP 62-053923, Derwent WPI Acc. No. 87-105816, March 9, 1987.					
	AF	Abstract of JP 05-236910, Derwent WPI Acc. No. 93-330545, September 17, 1993.					
	AG	Abstract of JP 07-059548, Derwent WPI Acc. No. 95-135875, March 7, 1995.					
	AH	Abstract of RU 2,008,015, Derwent WPI Acc. No. 94-277493, February 28, 1994.					
	AI	Anderson et al., "Generation of cAMP-Activated Chloride Currents by Expression of CFTR," <i>Science</i> 251: 679-682, February 8, 1991.					
	AJ	Brown et al., "Chemical chaperones correct the mutant phenotype of the $\Delta$ F508 cystic fibrosis transmembrane conductance regulator protein," <i>Cell Stress &amp; Chaperones</i> 1(2): 117-125, 1996.					
	AK	Hwang et al., "Genistein potentiates wild-type and $\Delta$ F508-CFTR channel activity," <i>American Journal of Physiology</i> 273(3, part 1): C988-C998, 1997.					
	AL	Ilek et al., "cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein," <i>American Journal of Physiology</i> 268(4 part 1): C886-C893, 1995.					
	AM	Knowles et al., "In Vivo Nasal Potential Difference: Techniques and Protocols for Assessing Efficacy of Gene Transfer in Cystic Fibrosis," <i>Human Gene Therapy</i> 6: 445-455, April 1995.					
	AN	Riordan et al., "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA," <i>Science</i> 245: 1066-1073, September 8, 1989.					
	AO	Rubenstein et al., "In Vitro Pharmacologic Restoration of CFTR-mediated Chloride Transport with Sodium 4-Phenylbutyrate in Cystic Fibrosis Epithelial Cells," <i>J. Clin. Invest.</i> 100(10): 2457-2465, November 1997.					
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).</p>							

RECEIVED

FEB 11 2002

Sheet 2

TECH CENTER 1600/2900

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
200116.403D1APPLICATION NO.  
09/982,315

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Horst Fisher and Beate Illek

FILING DATE

October 17, 2001

GROUP ART UNIT

1623

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BJ					
	BK					
	BL					
	BM					
	BN					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BO	Scott and Cooperstein, "Ascorbic acid stimulates chloride transport in the amphibian cornea," <i>Investigative Ophthalmology</i> 14(10): 763-766, October 1975.
	BP	Sheppard et al., "Mutations in CFTR associated with mild-disease-form Cl <sup>-</sup> channels with altered pore properties," <i>Nature</i> 362: 160-164, March 11, 1993.
	BQ	Smith, "Treatment of cystic fibrosis based on understanding CFTR," <i>J. Inher. Metab. Dis.</i> 18: 508-516, 1995.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

GA4/1623  
11Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**(To be used for all correspondence  
after initial filing)

Application Number	09/982,315
Filing Date	October 17, 2001
First Named Inventor	Horst Fischer
Group Art Unit	1623
Examiner Name	Not yet assigned
Attorney Docket No.	200116.403D1

**ENCLOSURES (check all that apply)**

- |   |   |   |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Response<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 (2 Sheets)<br><input checked="" type="checkbox"/> 18 Cited References<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53<br><input type="checkbox"/> Response to Missing Parts/Incomplete Application | <input type="checkbox"/> Assignment Papers (for an Application)<br><input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Request for Corrected Filing Receipt<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address<br><input type="checkbox"/> Declaration<br><input type="checkbox"/> Statement under 37 CFR 3.73(b)<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Small Entity Statement<br><input type="checkbox"/> Request for Refund | <input type="checkbox"/> CD(s), Number of CD(s) _____<br><input type="checkbox"/> After Allowance Communication to Group<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Return Receipt Postcard<br><input type="checkbox"/> Additional Enclosure(s) (please identify below):<br>_____<br>_____<br>_____<br>_____ |
|---|---|---|

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Individual Name Jane E.R. Potter, 33,332



00500

PATENT TRADEMARK OFFICE

Signature

Date

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name Shane F. Lambing

Signature

Date: